Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial

Donald Williams, G. A. Misbach, A. P. Kruse, T. D. Ivey

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.

Original languageEnglish
Pages (from-to)592-596
Number of pages5
JournalJournal of Thoracic and Cardiovascular Surgery
Volume90
Issue number4
StatePublished - Dec 1 1985
Externally publishedYes

Fingerprint

Myocardial Revascularization
Supraventricular Tachycardia
Verapamil
Placebos
Incidence
Oral Administration
Transplants
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial. / Williams, Donald; Misbach, G. A.; Kruse, A. P.; Ivey, T. D.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 90, No. 4, 01.12.1985, p. 592-596.

Research output: Contribution to journalArticle

@article{4996c6de6aa34ac39f930974aa4af1d2,
title = "Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial",
abstract = "To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.",
author = "Donald Williams and Misbach, {G. A.} and Kruse, {A. P.} and Ivey, {T. D.}",
year = "1985",
month = "12",
day = "1",
language = "English",
volume = "90",
pages = "592--596",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Oral verapamil for prophylaxis of supraventricular tachycardia after myocardial revascularization. A randomized trial

AU - Williams, Donald

AU - Misbach, G. A.

AU - Kruse, A. P.

AU - Ivey, T. D.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.

AB - To determine if the prophylactic administration or oral verapamil is effective in reducing the incidence of supraventricular tachycardia after myocardial revascularization, 141 patients were entered into a double-blind randomized trial. Seventy patients received verapamil 80 mg every 8 hours beginning immediately after operation and continuing for 5 days, and 71 patients received placebo. Patients were monitored during the study period and observed for the occurrence of supraventricular tachycardia. The verapamil and placebo groups were similar with regard to sex, age, preoperative antianginal drugs, number of bypass grafts, average bypass time, and average occlusion time. A total of 39 patients had supraventricular tachycardia, 20 were receiving verapamil, and 19 were receiving placebo. The average ventricular rate was 127 ± 13 beats/min for the verapamil group with supraventricular tachycardia compared with 140 ± 12 beats/min for the placebo group with the mean differences not significant (p = 0.10). On the basis of these data, it is concluded that verapamil 80 mg every 8 hours beginning early after myocardial revascularization is not effective in reducing the incidence of supraventricular tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0022387643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022387643&partnerID=8YFLogxK

M3 - Article

VL - 90

SP - 592

EP - 596

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 4

ER -